Exhibit 99.1 Bruker Reports Second Quarter 2024 Financial Results • Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy • Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy • Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy BILLERICA, Massachusetts – August 6, 2024 – Bruker Corporation (Nasdaq: BRKR) ...

For Immediate Release Chicago, IL – August 6, 2024 – Today, Zacks Equity Research discusses Mettler-Toledo International (MTD) and Bruker (BRKR) . Industry: Instruments – Scientific Link: https://www.zacks.com/commentary/2316245/2-instruments-stocks-to-watch-from-a-prospering-industry 2 Instruments Stocks to Watch From a Prospering Industry The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and lif ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Revenues are expected to be $796.23 million, up 16.8% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Earnings Whisper The Zacks ...

Bruker's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. Yet, the company's operations bear the brunt of excessive currency exposure and general macroeconomic headwinds. The stock carries a Zacks Rank #3 (Hold) at present. The CALID segment has been gaining from the strong demand for differentiated instruments, particularly life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments ...

Hims & Hers Heath stock has surged 181.7% in the past year. Estimates for the company's earnings have increased from 18 cents to 19 cents for 2024 and from 33 cents to 35 cents for 2025 in the past 30 days. On the flip side, Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. In add ...

Business leaders often talk about thinking big. But when it comes to nanotech stocks, the future is all about focusing on the small things. In terms of hard numbers, the global nanotech market reached a valuation of $3.69 billion in 2022. By 2030, the ecosystem could be worth $36.85 billion, or a compound annual growth rate (CAGR) of 33.1%. With projected expansion like that, it pays to at least consider these nanotech stocks. To be sure, VECO stock has already enjoyed a robust performance so far this year. ...

Bruker Corporation (BRKR) recently announced the launch of the neofleX Imaging Profiler for mass spectrometry-based tissue imaging at the 72nd ASMS meeting. The novel, high-performance MALDITOF/TOF system enables facile OME-TIFF file output via the new SCiLS Scope software and conveniently fits on a benchtop. The latest development is expected to significantly boost the company's Life Sciences Mass Spectrometry division within the Bruker Scientific Instruments ("BSI") CALID segment. About neofleX The neofle ...

ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company's attendance at the American Society for Mass Spectrometry (ASMS) Annual Conference from June 2nd to June 6th in Anaheim, CA, where the company will launch Spectronaut 19 and present major scientific and technological advances for its proprietary proteomics research software, services, and data insights solutions. Biogn ...

Bruker Corporation's (BRKR) strong growth reflects its fundamental commitment to innovate high-value solutions, and the ongoing portfolio transformation. However, macroeconomic issues dent profit. The stock carries a Zacks Rank #3 (Hold) currently. Bruker's CALID business has been gaining from the strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker's flagship timsTOF platform is a key dri ...

The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by aging demography, and continued innovation in the pharma and life sciences end-markets. Higher demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Industry participants like Mettler-Toledo International (MTD) and Bruker (BRKR) are gaining from the growing testing needs of newer biological drugs. Increased scrutiny of per and polyfluoroalkyl substances i ...